atezolizumab
roche
['immotion010', 'renal,(-adrenal)', 'atezo']
 the results of phase iii trial #immotion010, which assessed the use of atezolizumab as adjuvant treatment in patients with renal carcinoma with risk of relapse after tumour resection, were negative. learn more 
Leading translational research to accelerate & advance personalized and targeted therapies against cancer. 
@iCERCA centre